Compare Eni SpA (E) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs State Street SPDR S&P Biotech ETF — how do they compare? Eni SpA trades at $48.16 (market cap $70.34B), while State Street SPDR S&P Biotech ETF trades at $151.14. The key difference: Eni SpA pays a 4.99% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Eni SpA nearer its low. Which is the better fit depends on your goals.
| E | XBI | |
|---|---|---|
Market Cap | $70.34B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $57.61 | $164.28 |
52-Week Low | $32.93 | $85.16 |
Enterprise Value | $89.25B | — |
Dividend Yield | 4.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $48.11, down 2.91% over 24 hours, with a bullish technical signal supported by moving averages but mixed oscillators. The company shows stable cash flow generation with $238 million net cash flow in 2025, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent strategic moves include expanding into lithium, battery storage, and fusion energy partnerships, signaling diversification beyond traditional oil and gas.
The outlook balances diversification efforts against revenue pressures; the stock's low P/S of 0.79 and EV/EBITDA of 3.83 suggest undervaluation, but investors face risks from oil price volatility and execution challenges in new ventures. Analyst consensus is cautious with 61.53% hold ratings, reflecting uncertainty amid transition initiatives.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
